CHAMPIONS ONCOLOGY INC (CSBR) Stock Fundamental Analysis

NASDAQ:CSBR • US15870P3073

5.85 USD
-0.23 (-3.78%)
At close: Feb 17, 2026
6.24 USD
+0.39 (+6.67%)
After Hours: 2/10/2026, 4:30:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

CSBR gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. CSBR has only an average score on both its financial health and profitability. CSBR is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year CSBR was profitable.
  • In the past year CSBR had a positive cash flow from operations.
  • In multiple years CSBR reported negative net income over the last 5 years.
  • In multiple years CSBR reported negative operating cash flow during the last 5 years.
CSBR Yearly Net Income VS EBIT VS OCF VS FCFCSBR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M -10M

1.2 Ratios

  • With an excellent Return On Assets value of 8.26%, CSBR belongs to the best of the industry, outperforming 87.93% of the companies in the same industry.
  • CSBR's Return On Equity of 59.76% is amongst the best of the industry. CSBR outperforms 98.28% of its industry peers.
  • With an excellent Return On Invested Capital value of 24.26%, CSBR belongs to the best of the industry, outperforming 96.55% of the companies in the same industry.
Industry RankSector Rank
ROA 8.26%
ROE 59.76%
ROIC 24.26%
ROA(3y)-9.62%
ROA(5y)-5.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CSBR Yearly ROA, ROE, ROICCSBR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

1.3 Margins

  • Looking at the Profit Margin, with a value of 4.27%, CSBR is in the better half of the industry, outperforming 70.69% of the companies in the same industry.
  • In the last couple of years the Profit Margin of CSBR has grown nicely.
  • CSBR has a Operating Margin (4.22%) which is comparable to the rest of the industry.
  • In the last couple of years the Operating Margin of CSBR has grown nicely.
  • With a Gross Margin value of 50.11%, CSBR perfoms like the industry average, outperforming 53.45% of the companies in the same industry.
  • CSBR's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 4.22%
PM (TTM) 4.27%
GM 50.11%
OM growth 3Y89.93%
OM growth 5YN/A
PM growth 3Y94.62%
PM growth 5YN/A
GM growth 3Y-1.13%
GM growth 5Y1.11%
CSBR Yearly Profit, Operating, Gross MarginsCSBR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • CSBR has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for CSBR has been increased compared to 1 year ago.
  • The number of shares outstanding for CSBR has been increased compared to 5 years ago.
  • CSBR has a worse debt/assets ratio than last year.
CSBR Yearly Shares OutstandingCSBR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
CSBR Yearly Total Debt VS Total AssetsCSBR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

  • CSBR has an Altman-Z score of 0.33. This is a bad value and indicates that CSBR is not financially healthy and even has some risk of bankruptcy.
  • CSBR has a Altman-Z score (0.33) which is comparable to the rest of the industry.
  • The Debt to FCF ratio of CSBR is 0.03, which is an excellent value as it means it would take CSBR, only 0.03 years of fcf income to pay off all of its debts.
  • CSBR has a Debt to FCF ratio of 0.03. This is amongst the best in the industry. CSBR outperforms 93.10% of its industry peers.
  • CSBR has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • CSBR has a better Debt to Equity ratio (0.01) than 67.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.03
Altman-Z 0.33
ROIC/WACC2.24
WACC10.82%
CSBR Yearly LT Debt VS Equity VS FCFCSBR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M

2.3 Liquidity

  • A Current Ratio of 0.96 indicates that CSBR may have some problems paying its short term obligations.
  • CSBR has a worse Current ratio (0.96) than 86.21% of its industry peers.
  • A Quick Ratio of 0.96 indicates that CSBR may have some problems paying its short term obligations.
  • CSBR's Quick ratio of 0.96 is on the low side compared to the rest of the industry. CSBR is outperformed by 81.03% of its industry peers.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.96
CSBR Yearly Current Assets VS Current LiabilitesCSBR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 3200.00% over the past year.
  • Measured over the past years, CSBR shows a very strong growth in Earnings Per Share. The EPS has been growing by 146.62% on average per year.
  • Looking at the last year, CSBR shows a quite strong growth in Revenue. The Revenue has grown by 9.06% in the last year.
  • The Revenue has been growing by 12.13% on average over the past years. This is quite good.
EPS 1Y (TTM)3200%
EPS 3Y146.62%
EPS 5YN/A
EPS Q2Q%-60%
Revenue 1Y (TTM)9.06%
Revenue growth 3Y5.06%
Revenue growth 5Y12.13%
Sales Q2Q%11.5%

3.2 Future

  • The Earnings Per Share is expected to decrease by -52.39% on average over the next years. This is quite bad
  • CSBR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.26% yearly.
EPS Next Y-72.8%
EPS Next 2Y-52.39%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.41%
Revenue Next 2Y7.38%
Revenue Next 3Y18.44%
Revenue Next 5Y18.26%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CSBR Yearly Revenue VS EstimatesCSBR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20M 40M 60M 80M 100M
CSBR Yearly EPS VS EstimatesCSBR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 17.73 indicates a rather expensive valuation of CSBR.
  • 89.66% of the companies in the same industry are more expensive than CSBR, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of CSBR to the average of the S&P500 Index (27.16), we can say CSBR is valued slightly cheaper.
  • With a Price/Forward Earnings ratio of 57.35, CSBR can be considered very expensive at the moment.
  • CSBR's Price/Forward Earnings ratio is in line with the industry average.
  • CSBR's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.10.
Industry RankSector Rank
PE 17.73
Fwd PE 57.35
CSBR Price Earnings VS Forward Price EarningsCSBR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CSBR is valued a bit cheaper than 75.86% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, CSBR is valued cheaply inside the industry as 89.66% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 14.41
EV/EBITDA 18.36
CSBR Per share dataCSBR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

  • CSBR has a very decent profitability rating, which may justify a higher PE ratio.
  • A cheap valuation may be justified as CSBR's earnings are expected to decrease with -52.39% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-52.39%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CSBR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CHAMPIONS ONCOLOGY INC

NASDAQ:CSBR (2/17/2026, 8:07:41 PM)

After market: 6.24 +0.39 (+6.67%)

5.85

-0.23 (-3.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)12-15
Earnings (Next)03-09
Inst Owners47.27%
Inst Owner Change2.33%
Ins Owners26.55%
Ins Owner Change0%
Market Cap81.26M
Revenue(TTM)58.42M
Net Income(TTM)2.49M
Analysts82.86
Price Target12.24 (109.23%)
Short Float %0.75%
Short Ratio5.95
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)196.08%
Min EPS beat(2)96.08%
Max EPS beat(2)296.08%
EPS beat(4)4
Avg EPS beat(4)1021.81%
Min EPS beat(4)65.69%
Max EPS beat(4)3629.41%
EPS beat(8)7
Avg EPS beat(8)610.2%
EPS beat(12)8
Avg EPS beat(12)364.99%
EPS beat(16)10
Avg EPS beat(16)253.89%
Revenue beat(2)2
Avg Revenue beat(2)3.27%
Min Revenue beat(2)1.54%
Max Revenue beat(2)5.01%
Revenue beat(4)4
Avg Revenue beat(4)9.14%
Min Revenue beat(4)0.83%
Max Revenue beat(4)29.17%
Revenue beat(8)7
Avg Revenue beat(8)4.71%
Revenue beat(12)7
Avg Revenue beat(12)1.27%
Revenue beat(16)10
Avg Revenue beat(16)1.37%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-45.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.13%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.3%
Valuation
Industry RankSector Rank
PE 17.73
Fwd PE 57.35
P/S 1.39
P/FCF 14.41
P/OCF 13.06
P/B 19.49
P/tB 21.19
EV/EBITDA 18.36
EPS(TTM)0.33
EY5.64%
EPS(NY)0.1
Fwd EY1.74%
FCF(TTM)0.41
FCFY6.94%
OCF(TTM)0.45
OCFY7.66%
SpS4.21
BVpS0.3
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.49
Profitability
Industry RankSector Rank
ROA 8.26%
ROE 59.76%
ROCE 30.71%
ROIC 24.26%
ROICexc N/A
ROICexgc N/A
OM 4.22%
PM (TTM) 4.27%
GM 50.11%
FCFM 9.65%
ROA(3y)-9.62%
ROA(5y)-5.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y89.93%
OM growth 5YN/A
PM growth 3Y94.62%
PM growth 5YN/A
GM growth 3Y-1.13%
GM growth 5Y1.11%
F-Score7
Asset Turnover1.94
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.03
Debt/EBITDA 0.01
Cap/Depr 38.69%
Cap/Sales 1%
Interest Coverage 250
Cash Conversion 156.75%
Profit Quality 226.32%
Current Ratio 0.96
Quick Ratio 0.96
Altman-Z 0.33
F-Score7
WACC10.82%
ROIC/WACC2.24
Cap/Depr(3y)65.35%
Cap/Depr(5y)124.01%
Cap/Sales(3y)2.56%
Cap/Sales(5y)4.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3200%
EPS 3Y146.62%
EPS 5YN/A
EPS Q2Q%-60%
EPS Next Y-72.8%
EPS Next 2Y-52.39%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)9.06%
Revenue growth 3Y5.06%
Revenue growth 5Y12.13%
Sales Q2Q%11.5%
Revenue Next Year3.41%
Revenue Next 2Y7.38%
Revenue Next 3Y18.44%
Revenue Next 5Y18.26%
EBIT growth 1Y799.72%
EBIT growth 3Y99.53%
EBIT growth 5YN/A
EBIT Next Year-50.29%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y216.22%
FCF growth 3Y19.31%
FCF growth 5Y58.93%
OCF growth 1Y346.75%
OCF growth 3Y4.35%
OCF growth 5Y20.48%

CHAMPIONS ONCOLOGY INC / CSBR FAQ

What is the fundamental rating for CSBR stock?

ChartMill assigns a fundamental rating of 5 / 10 to CSBR.


Can you provide the valuation status for CHAMPIONS ONCOLOGY INC?

ChartMill assigns a valuation rating of 4 / 10 to CHAMPIONS ONCOLOGY INC (CSBR). This can be considered as Fairly Valued.


Can you provide the profitability details for CHAMPIONS ONCOLOGY INC?

CHAMPIONS ONCOLOGY INC (CSBR) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for CSBR stock?

The Price/Earnings (PE) ratio for CHAMPIONS ONCOLOGY INC (CSBR) is 17.73 and the Price/Book (PB) ratio is 19.49.


What is the expected EPS growth for CHAMPIONS ONCOLOGY INC (CSBR) stock?

The Earnings per Share (EPS) of CHAMPIONS ONCOLOGY INC (CSBR) is expected to decline by -72.8% in the next year.